Bulletin
Investor Alert

NeuroSense Therapeutics Ltd.

NAS: NRSN

GO
/marketstate/country/us

Market closed

 --Quotes are delayed by 20 min

Nov 30, 2022, 3:44 p.m.

/zigman2/quotes/230850337/composite

$

1.72

Change

+0.04 +2.37%

Volume

Volume 9,332

Quotes are delayed by 20 min

/zigman2/quotes/230850337/composite

Previous close

$ 1.68

$ 1.72

Change

+0.04 +2.37%

Day low

Day high

$1.68

$1.74

Open

52 week low

52 week high

$1.23

$8.18

Open

Company Description

Neurosense Therapeutics Ltd. is a clinical-stage biotechnology company. The firm is focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases. It is involved in the 2b/3 clinical trial using its product candidate, PrimeC in patients with ALS...

Neurosense Therapeutics Ltd. is a clinical-stage biotechnology company. The firm is focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases. It is involved in the 2b/3 clinical trial using its product candidate, PrimeC in patients with ALS and also commencing research into other possible indications for the drug, including Alzheimer’s and Parkinson’s diseases. The company was founded by Alon Ben-Noon on February 13, 2017 and is headquartered in Herzliya, Israel.

Valuation

Price to Book Ratio

2.99

Enterprise Value to EBITDA

-1.85

Efficiency

Liquidity

Current Ratio

19.12

Quick Ratio

19.12

Cash Ratio

18.60

Profitability

Return on Assets

-66.19

Return on Equity

-83.62

Return on Total Capital

-97.22

Capital Structure

Total Debt to Total Assets

15.99

Officers and Executives

Name Age Officer Since Title
Mr. Alon Ben-Noon 42 2017 Chairman, Chief Executive Officer & Director
Mr. Or Eisenberg 40 2021 Chief Financial Officer
Dr. Oron Yacoby-Zeevi 60 - Chief Scientific Officer
Dr. Ferenc Tracik 57 2021 Chief Medical Officer
Ms. Irit Shefer - 2022 Head-Clinical Operations

Insider Actions

– Purchase – Sale 1 – Number of Transactions
/news/latest/company/us/nrsn

MarketWatch News on NRSN

  1. NeuroSense Therapeutics started at buy with $7 stock price target at Maxim Group

    7:32 a.m. Jan. 7, 2022

    - Tomi Kilgore

/news/nonmarketwatch/company/us/nrsn

Other News on NRSN

  1. CELU, CDAK and VLCN among mid-day movers

    12:17 p.m. June 30, 2022

    - Seeking Alpha

  2. EVFM, DTIL and SRRK among mid-day movers

    11:34 a.m. June 27, 2022

    - Seeking Alpha

  3. NeuroSense receives ~$4M from warrant exercise

    7:18 a.m. March 25, 2022

    - Seeking Alpha

  4. VICR, AEHL and ADTH among mid-day movers

    12:01 p.m. March 23, 2022

    - Seeking Alpha

  5. IQ, NEW and QNRX among mid-day movers

    11:35 a.m. March 22, 2022

    - Seeking Alpha

  6. YMTX, YQ and VLON among mid-day movers

    11:29 a.m. March 21, 2022

    - Seeking Alpha

  7. SUNW, CEI and HNRG among mid-day movers

    12:33 p.m. March 7, 2022

    - Seeking Alpha

  8. EVBG, IRNT and NTRB among mid-day movers

    12:37 p.m. Feb. 28, 2022

    - Seeking Alpha

  9. PLUG, BLDP and BE among pre market gainers

    8:37 a.m. Feb. 28, 2022

    - Seeking Alpha

At a Glance

Neurosense Therapeutics Ltd.

11 HaMenofim Street

Building B

Herzliya, TA 46725

Phone

972 97996183

Industry

Biotechnology

Sector

Health Care/Life Sciences

Fiscal Year-end

12/2022

Revenue

N/A

Net Income

$-4.04M

Employees

-

/news/pressrelease/company/us/nrsn

Press Releases on NRSN

  1. NeuroSense Receives FDA Clearance of IND for its ALS Phase 2b Study

    8:30 a.m. Nov. 15, 2022

    - PR Newswire - PRF

  2. NeuroSense Therapeutics CEO Provides Key Corporate Update Video

    7:30 a.m. July 18, 2022

    - PR Newswire - PRF

  3. 3 Penny Stocks To Watch While The Stock Market Is Down

    8:29 a.m. June 30, 2022

    - Penny Stocks

  4. 3 Penny Stocks To Watch After GDP Report

    9:04 a.m. June 29, 2022

    - Penny Stocks

  5. Loading more headlines...
Link to MarketWatch's Slice.